The clinical usefulness of knowing CHRNA5 polymorphism genotype: paving the way for personalized therapy.

doi:10.1177/03008916251408279

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The clinical usefulness of knowing CHRNA5 polymorphism genotype: paving the way for personalized therapy.

Tumori - 1 Jun 2026

Colombo Francesca, Veronese Chiara, Munarini Elena, Paolino Cinzia, Maspero Davide, Mangano Nunzia, Esposito Martina, Minnai Francesca, Noci Sara, Giussani Marta, Morelli Daniele, Cardani Elisa, Esposito Alessandro, Sacco Gaia Giulia Angela, Spitaleri Debora, Boffi Roberto

Abstract excerpt

BACKGROUND: Tobacco smoking is a leading cause of global mortality, with cessation being the primary prevention strategy. Nicotine addiction has a genetic component; the rs503464 single nucleotide polymorphism (SNP) in the CHRNA5 gene is associated with smoking cessation therapy success. However, the impact of communicating genetic risk to patients remains unclear. This study evaluated whether knowledge of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nerve Tissue Proteins

Share to Polymorphism, Single Nucleotide

Share to Precision Medicine

Share to Receptors, Nicotinic

Share to Smoking

Share to Smoking Cessation

Share to Tobacco Use Disorder

Source

Open in PubMed Open full text

Identifiers

PMID: 41808243
DOI: 10.1177/03008916251408279
PMCID: PMC13250266

Genes

CHRNA5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical usefulness of knowing CHRNA5 polymorphism genotype: paving the way for personalized therapy.PMID 41808243Read ↗

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.Semantic proximity Read ↗

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.Semantic proximity Read ↗

Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking.Semantic proximity Read ↗

Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled TrialSemantic proximity Read ↗

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Semantic proximity Read ↗

Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis.Semantic proximity Read ↗

Smoking cessation treatment: pharmacogenetic assessment.Semantic proximity Read ↗

Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.Semantic proximity Read ↗

Proof of Concept of a Personalized Genetic Risk Tool to Promote Smoking Cessation: High Acceptability and Reduced Cigarette Smoking.Semantic proximity Read ↗

Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.